Literature DB >> 16310189

Mouse model of sustained elevation in intraocular pressure produced by episcleral vein occlusion.

Javier Ruiz-Ederra1, A S Verkman.   

Abstract

We have developed an inducible mouse model of glaucoma based on episcleral vein cauterization (EVC). Intraocular pressure (IOP) elevation in adult mice was produced by cauterizing three episcleral veins. Serial IOP measurements were done by induction-impact tonometry. IOP was significantly elevated by 104+/-20% in 20 out of 23 mice (87%) within the first day after EVC, and remained elevated for 4 weeks, with mean IOP 94% higher in EVC-treated vs. contralateral control eyes. Aqueous outflow blockade was verified from the IOP response to pulsed fluid infusions into the anterior chamber. Retinal ganglion cell (RGC) loss, determined by retrograde labelling using Fluoro-Gold applied to the superior colliculous, was approximately 20% at 2 weeks after EVC. We conclude that episcleral vein occlusion in mice produces significant and sustained elevation in IOP associated with increased outflow resistance and RGC loss, and thus may be useful to model glaucoma in genetically modified and drug-treated mice.

Entities:  

Mesh:

Year:  2005        PMID: 16310189     DOI: 10.1016/j.exer.2005.10.019

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  39 in total

Review 1.  Aqueous humor outflow: dynamics and disease.

Authors:  Uttio Roy Chowdhury; Cheryl R Hann; W Daniel Stamer; Michael P Fautsch
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-05       Impact factor: 4.799

2.  Differential susceptibility to experimental glaucoma among 3 mouse strains using bead and viscoelastic injection.

Authors:  Frances E Cone; Scott E Gelman; Janice L Son; Mary E Pease; Harry A Quigley
Journal:  Exp Eye Res       Date:  2010-06-26       Impact factor: 3.467

3.  Glaucoma-induced degeneration of retinal ganglion cells prevented by hypoxic preconditioning: a model of glaucoma tolerance.

Authors:  Yanli Zhu; Lihong Zhang; Jimena F Schmidt; Jeffrey M Gidday
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

4.  Prolonged elevation of intraocular pressure results in retinal ganglion cell loss and abnormal retinal function in mice.

Authors:  A Kareem Khan; Dennis Y Tse; Meike E van der Heijden; Priya Shah; Derek M Nusbaum; Zhuo Yang; Samuel M Wu; Benjamin J Frankfort
Journal:  Exp Eye Res       Date:  2014-11-18       Impact factor: 3.467

5.  Reduction of ER stress via a chemical chaperone prevents disease phenotypes in a mouse model of primary open angle glaucoma.

Authors:  Gulab S Zode; Markus H Kuehn; Darryl Y Nishimura; Charles C Searby; Kabhilan Mohan; Sinisa D Grozdanic; Kevin Bugge; Michael G Anderson; Abbot F Clark; Edwin M Stone; Val C Sheffield
Journal:  J Clin Invest       Date:  2011-08-08       Impact factor: 14.808

6.  Elevated intracranial pressure causes optic nerve and retinal ganglion cell degeneration in mice.

Authors:  Derek M Nusbaum; Samuel M Wu; Benjamin J Frankfort
Journal:  Exp Eye Res       Date:  2015-04-23       Impact factor: 3.467

7.  Elevated intraocular pressure causes inner retinal dysfunction before cell loss in a mouse model of experimental glaucoma.

Authors:  Benjamin J Frankfort; A Kareem Khan; Dennis Y Tse; Inyoung Chung; Ji-Jie Pang; Zhuo Yang; Ronald L Gross; Samuel M Wu
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-28       Impact factor: 4.799

8.  RGS2-deficient mice exhibit decreased intraocular pressure and increased retinal ganglion cell survival.

Authors:  Miyuki Inoue-Mochita; Toshihiro Inoue; David L Epstein; Kendall J Blumer; Ponugoti V Rao
Journal:  Mol Vis       Date:  2009-03-06       Impact factor: 2.367

Review 9.  Rodent models of glaucoma.

Authors:  Thomas V Johnson; Stanislav I Tomarev
Journal:  Brain Res Bull       Date:  2009-04-18       Impact factor: 4.077

Review 10.  Mouse models of retinal ganglion cell death and glaucoma.

Authors:  Stuart J McKinnon; Cassandra L Schlamp; Robert W Nickells
Journal:  Exp Eye Res       Date:  2008-12-07       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.